The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Multiple Sclerosis Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
The global Multiple Sclerosis Therapeutics market size is expected to reach US$ 19600 million by 2029, growing at a CAGR of 2.0% from 2023 to 2029. The market is mainly driven by the significant applications of Multiple Sclerosis Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and e-Commerce,, are propelling Multiple Sclerosis Therapeutics market. Beta Interferon, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Multiple Sclerosis Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Multiple Sclerosis Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Multiple Sclerosis Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Multiple Sclerosis Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Multiple Sclerosis Therapeutics covered in this report include Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck and AbbVie, etc.
The global Multiple Sclerosis Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Teva Pharmaceuticals
Sanofi Genzyme
Bayer
Pfizer
Biogen Idec
Merck
AbbVie
Global Multiple Sclerosis Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Multiple Sclerosis Therapeutics market, Segment by Type:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
Global Multiple Sclerosis Therapeutics market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Multiple Sclerosis Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
The global Multiple Sclerosis Therapeutics market size is expected to reach US$ 19600 million by 2029, growing at a CAGR of 2.0% from 2023 to 2029. The market is mainly driven by the significant applications of Multiple Sclerosis Therapeutics in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and e-Commerce,, are propelling Multiple Sclerosis Therapeutics market. Beta Interferon, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Distribution Channel. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Multiple Sclerosis Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Multiple Sclerosis Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Multiple Sclerosis Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Multiple Sclerosis Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Multiple Sclerosis Therapeutics covered in this report include Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck and AbbVie, etc.
The global Multiple Sclerosis Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Teva Pharmaceuticals
Sanofi Genzyme
Bayer
Pfizer
Biogen Idec
Merck
AbbVie
Global Multiple Sclerosis Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Multiple Sclerosis Therapeutics market, Segment by Type:
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agents
Others
Global Multiple Sclerosis Therapeutics market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
e-Commerce
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Multiple Sclerosis Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Multiple Sclerosis Therapeutics
1.1 Multiple Sclerosis Therapeutics Market Overview
1.1.1 Multiple Sclerosis Therapeutics Product Scope
1.1.2 Multiple Sclerosis Therapeutics Market Status and Outlook
1.2 Global Multiple Sclerosis Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Multiple Sclerosis Therapeutics Market Size by Region (2018-2029)
1.4 Global Multiple Sclerosis Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Multiple Sclerosis Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Multiple Sclerosis Therapeutics Market Size (2018-2029)
1.6.1 North America Multiple Sclerosis Therapeutics Market Size (2018-2029)
1.6.2 Europe Multiple Sclerosis Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Multiple Sclerosis Therapeutics Market Size (2018-2029)
1.6.4 Latin America Multiple Sclerosis Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Multiple Sclerosis Therapeutics Market Size (2018-2029)
2 Multiple Sclerosis Therapeutics Market by Type
2.1 Introduction
2.1.1 Beta Interferon
2.1.2 Corticosteroids
2.1.3 Monoclonal Antibodies
2.1.4 Antineoplastic Agents
2.1.5 Others
2.2 Global Multiple Sclerosis Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Multiple Sclerosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Multiple Sclerosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Multiple Sclerosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Multiple Sclerosis Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Multiple Sclerosis Therapeutics Revenue Breakdown by Type (2018-2029)
3 Multiple Sclerosis Therapeutics Market Overview by Distribution Channel
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 e-Commerce
3.2 Global Multiple Sclerosis Therapeutics Market Size by Distribution Channel: 2018 VS 2022 VS 2029
3.2.1 Global Multiple Sclerosis Therapeutics Historic Market Size by Distribution Channel (2018-2023)
3.2.2 Global Multiple Sclerosis Therapeutics Forecasted Market Size by Distribution Channel (2024-2029)
3.3 Key Regions Market Size by Distribution Channel
3.3.1 North America Multiple Sclerosis Therapeutics Revenue Breakdown by Distribution Channel (2018-2029)
3.3.2 Europe Multiple Sclerosis Therapeutics Revenue Breakdown by Distribution Channel (2018-2029)
3.3.3 Asia-Pacific Multiple Sclerosis Therapeutics Revenue Breakdown by Distribution Channel (2018-2029)
3.3.4 Latin America Multiple Sclerosis Therapeutics Revenue Breakdown by Distribution Channel (2018-2029)
3.3.5 Middle East and Africa Multiple Sclerosis Therapeutics Revenue Breakdown by Distribution Channel (2018-2029)
4 Multiple Sclerosis Therapeutics Competition Analysis by Players
4.1 Global Multiple Sclerosis Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Multiple Sclerosis Therapeutics as of 2022)
4.3 Date of Key Players Enter into Multiple Sclerosis Therapeutics Market
4.4 Global Top Players Multiple Sclerosis Therapeutics Headquarters and Area Served
4.5 Key Players Multiple Sclerosis Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Multiple Sclerosis Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Multiple Sclerosis Therapeutics Products, Services and Solutions
5.1.4 Novartis Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Teva Pharmaceuticals
5.2.1 Teva Pharmaceuticals Profile
5.2.2 Teva Pharmaceuticals Main Business
5.2.3 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Products, Services and Solutions
5.2.4 Teva Pharmaceuticals Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Teva Pharmaceuticals Recent Developments
5.3 Sanofi Genzyme
5.3.1 Sanofi Genzyme Profile
5.3.2 Sanofi Genzyme Main Business
5.3.3 Sanofi Genzyme Multiple Sclerosis Therapeutics Products, Services and Solutions
5.3.4 Sanofi Genzyme Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer Recent Developments
5.4 Bayer
5.4.1 Bayer Profile
5.4.2 Bayer Main Business
5.4.3 Bayer Multiple Sclerosis Therapeutics Products, Services and Solutions
5.4.4 Bayer Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Multiple Sclerosis Therapeutics Products, Services and Solutions
5.5.4 Pfizer Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 Biogen Idec
5.6.1 Biogen Idec Profile
5.6.2 Biogen Idec Main Business
5.6.3 Biogen Idec Multiple Sclerosis Therapeutics Products, Services and Solutions
5.6.4 Biogen Idec Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Biogen Idec Recent Developments
5.7 Merck
5.7.1 Merck Profile
5.7.2 Merck Main Business
5.7.3 Merck Multiple Sclerosis Therapeutics Products, Services and Solutions
5.7.4 Merck Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Merck Recent Developments
5.8 AbbVie
5.8.1 AbbVie Profile
5.8.2 AbbVie Main Business
5.8.3 AbbVie Multiple Sclerosis Therapeutics Products, Services and Solutions
5.8.4 AbbVie Multiple Sclerosis Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 AbbVie Recent Developments
6 North America
6.1 North America Multiple Sclerosis Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Multiple Sclerosis Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Multiple Sclerosis Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Multiple Sclerosis Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Multiple Sclerosis Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Multiple Sclerosis Therapeutics Market Dynamics
11.1 Multiple Sclerosis Therapeutics Industry Trends
11.2 Multiple Sclerosis Therapeutics Market Drivers
11.3 Multiple Sclerosis Therapeutics Market Challenges
11.4 Multiple Sclerosis Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
